Big Money Are Not Betting On Corcept Therapeutics Inc (NASDAQ:CORT), Sentiment at 1.18

Corcept Therapeutics Incorporated (NASDAQ:CORT) Corporate Logo

Corcept Therapeutics Inc’s Sentiment

In 2018 Q2 Corcept Therapeutics Inc (NASDAQ:CORT) big money sentiment decreased to 1.18, SEC filings reveal. So its down -0.10, from 2018Q1’s 1.28. 97 institutional investors started new and increased equity positions, while 82 reduced and sold their stakes in Corcept Therapeutics Inc so the sentiment dropped. These funds own 85.22 million shares, that’s up from 84.82 million shares in 2018Q1. Funds holding Corcept Therapeutics Inc in top 10 changed to 2 from 4 for a decrease of 2. In total 23 funds closed positions, 59 reduced and 64 increased. Also 33 funds bought new Corcept Therapeutics Inc stakes.

Biggest Corcept Therapeutics Inc Investors

As of 2018 Q2 Ingalls & Snyder Llc has 5.34% invested in Corcept Therapeutics Inc. As of 2018 Q2, 4.63 million shares of Corcept Therapeutics Inc are owned by Consonance Capital Management Lp. In addition, Tanaka Capital Management Inc reported 88,154 shares in Corcept Therapeutics Inc equivalent to 3.32% of its fund portfolio. S&T Bank Pa revealed 397,769 shares position in Corcept Therapeutics Inc. The Ohio-based fund Shaker Investments Llc Oh looks positive on Corcept Therapeutics Inc, having 107,640 shares.

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States.The company has $1.51 billion market cap. It offers Korlym tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.The P/E ratio is 10.92. The firm is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer.

At traded at $13.04 lastly.It’s downtrending since December 8, 2017 and is 21.11% down. CORT underperformed by 36.73% the S&P500.

On February, 28. Investors expect Corcept Therapeutics Incorporated (NASDAQ:CORT) to publish its quarterly earnings, according to RTT. Analysts expect change of 0.00 % or $0.00 from previous year’s $0.17 EPS compared to current’s $0.17 EPS. The profit will be $19.63 million for CORT if $0.17 EPS becomes true. After $0.14 EPS report last quarter, Wall Street now sees 21.43 % EPS growth of Corcept Therapeutics Incorporated.

564,236 were reported by Ameriprise Fincl. Navellier & Incorporated accumulated 114,041 shs. Sei Invests has invested 0% of its capital in Corcept Therapeutics Incorporated (NASDAQ:CORT). The Connecticut-based Trexquant Lp has invested 0.02% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Stifel Corp, Missouri-based fund reported 12,130 shs. Mason Street Advsr Limited Com accumulated 0.01% or 27,620 shs. Smith Asset Mngmt Group Inc L P accumulated 96,865 shs. State Street invested 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Moreover, Wells Fargo And Mn has 0% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 697,851 shs. Hl Financial Serv Limited Liability Company has invested 0.05% of its capital in Corcept Therapeutics Incorporated (NASDAQ:CORT). Louisiana State Employees Retirement Systems has 42,800 shs for 0.03% of their capital. Citigroup accumulated 0% or 206,035 shs. Buckingham Asset Management Limited Liability Corporation has invested 0.05% of its capital in Corcept Therapeutics Incorporated (NASDAQ:CORT). Capital Impact Llc accumulated 117,439 shs. Schwab Charles Management stated it has 501,937 shs or 0.01% of all its holdings.

Corcept Therapeutics Incorporated had 4 sales and 4 buys since June 7, 2018. This’s net activity of $4.85 million. BAKER G LEONARD JR bought 100,000 shs worth $1.27M.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Ratings Coverage

In total 2 analysts cover Corcept Therapeutics Inc (NASDAQ:CORT). “Buy” rating has 1, “Sell” are 0, while 1 are “Hold”. (NASDAQ:CORT) has 50% bullish analysts. 4 are the (NASDAQ:CORT)’s ratings reports on 8 Dec 2018 according to StockzIntelligence Inc. In Tuesday, June 19 report FBR Capital maintained the stock with “Buy” rating. The company rating was maintained by FBR Capital on Monday, August 13. On Tuesday, June 12 FBR Capital maintained Corcept Therapeutics Incorporated (NASDAQ:CORT) rating. FBR Capital has “Buy” rating and $3000 target.

For more Corcept Therapeutics Incorporated (NASDAQ:CORT) news posted briefly go to: Seekingalpha.com, Seekingalpha.com, Seekingalpha.com, Zacks.com or Nasdaq.com. The titles are as follows: “Corcept Therapeutics – Growth Investor’s Biotech Pick – Seeking Alpha” posted on September 20, 2018, “Corcept medical chief to depart – Seeking Alpha” on November 19, 2018, “Corcept Therapeutics’ (CORT) CEO Joseph Belanoff on Q1 2018 Results – Earnings Call Transcript – Seeking Alpha” with a publish date: May 08, 2018, “Options Traders Expect Huge Moves in Corcept Therapeutics (CORT) Stock – Zacks.com” and the last “Notable Wednesday Option Activity: CORT, ADBE, ZN – Nasdaq” with publication date: August 01, 2018.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.